Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Liabilities and Shareholders Equity (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Liabilities and Shareholders Equity for 2 consecutive years, with $105.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 45.93% to $105.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $521.9 million, a N/A change, with the full-year FY2024 number at $157.2 million, changed N/A from a year prior.
  • Liabilities and Shareholders Equity was $105.6 million for Q3 2025 at Pyxis Oncology, down from $123.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $220.2 million in Q1 2024 to a low of $105.6 million in Q3 2025.